Sage Journals: Discover world-class research

Abstract

Background:

Natalizumab and fingolimod have not been compared in controlled trials but only in observational studies, with inconclusive results.

Objectives:

The objective of this study is to compare the effect of natalizumab and fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS).

Methods:

We included all consecutive RRMS patients switched from first-line agents (glatiramer acetate/interferons) to natalizumab or fingolimod, with a follow-up of 24 months. Data of relapses, Expanded Disability Status Scale score and brain magnetic resonance imaging (MRI) scans were collected. We used propensity score (PS) matching and intention-to-treat analysis.

Results:

We retained 102 patients in each cohort after PS matching, with similar baseline characteristics. More patients discontinued natalizumab compared to fingolimod (33% vs 11%, p < 0.001), mainly for progressive multifocal leukoencephalopathy (PML) concern. No serious adverse events occurred in the two cohorts. Compared to fingolimod, the natalizumab group presented a higher percentage of relapse-free patients (66% vs 80%, p = 0.015), a higher percentage of disability-improved patients (6% vs 15%, p = 0.033), a lower percentage of MRI-active patients (38% vs 14%, p = 0.001) and a higher percentage of patients with no evidence of disease activity (NEDA-3; 44% vs 70%, p < 0.001) after 2 years of follow-up. Disability worsening was not statistically different in the two groups.

Conclusion:

Natalizumab is superior to fingolimod in RRMS patients non-responding to first-line agents.

Keywords

Multiple sclerosis natalizumab fingolimod comparison second line

Get full access to this article

View all access options for this article.

References

Polman

O’Connor

Havrdova

. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Calabresi

Radue

Goodin

. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545–556.

Kappos

Radue

O’Connor

. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

Cohen

Barkhof

Comi

. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

Totaro

Di Carmine

Costantino

. Fingolimod treatment in relapsing-remitting multiple sclerosis patients: A prospective observational multicenter postmarketing study. Mult Scler Int 2015; 2015: 763418.

Hersh

Hara-Cleaver

Rudick

. Experience with fingolimod in clinical practice. Int J Neurosci. Epub ahead of print 29 October 2014. DOI: 10.3109/00207454.2014.969839.

Cohen

Khatri

Barkhof

. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. Epub ahead of print 25 June 2015. DOI: 10.1136/jnnp-2015-310597.

Sangalli

Moiola

Bucello

. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: A post-marketing observational study. Neurol Sci 2011; 31(Suppl. 3): 299–302.

Outteryck

Ongagna

Brochet

. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: Clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol 2014; 21: 40–48.

10.

Butzkueven

Kappos

Pellegrini

. Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85: 1190–1197.

11.

Bergvall

Makin

Lahoz

. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: A US claims database study. PLoS ONE 2014; 9: e88472.

12.

Spelman

Jokubaitis

. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol 2015; 72: 405–413.

13.

Spelman

Kalincik

Zhang

. Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol 2015; 2: 373–387.

14.

European Medicines Agency. Tysabri (natalizumab): Summary of product characteristics, 2012, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf (accessed 21 March 2015).

15.

European Medicines Agency. Gilenya 0.5 mg hard capsules: Summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf (accessed 5 April 2015).

16.

O’Connor

Goodman

Kappos

. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 2014; 83: 78–86.

17.

Baldwin

Hogg

. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr Opin Neurol 2013; 26: 318–323.

18.

Sorensen

Bertolotto

Edan

. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18: 143–152.

19.

Plavina

Subramanyam

Bloomgren

. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76: 802–812.

20.

Espinosa

Berger

. Delayed fingolimod-associated asystole. Mult Scler 2011; 17: 1387–1389.

21.

Lindsey

Haden-Pinneri

Memon

. Sudden unexpected death on fingolimod. Mult Scler 2012; 18: 1507–1508.

22.

Schurmann

Basra

Awar

. Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. Mult Scler Relat Disord 2014; 3: 408–412.

23.

Brooks

. Third case of PML with fingolimod (Gilenya) in MS. Medscape Medical News, 18 August 2015, http://www.medscape.com/viewarticle/849677 (accessed 20 September 2015).

24.

Bergvall

Lahoz

Reynolds

. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: A retrospective US claims database analysis. Curr Med Res Opin 2014; 30: 1461–1471.

25.

Braune

Lang

Bergmann

. Second line use of fingolimod is as effective as natalizumab in a German out-patient RRMS-cohort. J Neurol 2013; 260: 2981–2985.

26.

Carruthers

Rotstein

Healy

. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler 2014; 20: 1381–1390.

27.

Gajofatto

Bianchi

Deotto

. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. Eur Neurol 2014; 72: 173–180.

28.

Kalincik

Horakova

Spelman

. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015; 77: 425–435.

29.

The impact of natalizumab versus fingolimod on central nervous system (CNS) tissue damage and recovery in active relapsing-remitting multiple sclerosis (RRMS) subjects (REVEAL). ClinicalTrials.gov Identifier: NCT02342704, https://clinicaltrials.gov/ct2/show/NCT02342704?term =natalizumab+fingolimod&rank=2 (accessed 26 April 2015).

30.

D’Agostino

Jr . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265–2281.

31.

Love

. Explaining post-propensity score covariate balance. Center for Health Care Research & Policy, Case Western Reserve University and ENAR, 1 April 2003, http://www.chrp.org/love/handoutenar2003.pdf (accessed March 2016).

32.

Cohen

. Statistical power analysis for the behavioral sciences (Chapter 2). Toronto, ON, Canada: Academic Press, Inc., 1977.

33.

Miravalle

Jensen

Kinkel

. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68: 186–191.

34.

O’Connor

Goodman

Kappos

. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858–1865.

35.

Prosperini

Gianni

Barletta

. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci 2012; 323: 104–112.

36.

Rudick

Lee

Cutter

. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: Eight-year follow-up. Arch Neurol 2010; 67: 1329–1335.

37.

Kappos

Kuhle

Multanen

. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry 2015; 86: 1202–1207.

38.

Prosperini

Annovazzi

Capobianco

. Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Mult Scler 2015; 21: 1713–1722.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.37 MB

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

Abstract

Background:

Objectives:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material